share_log

Steven A. Shallcross Purchases 25,000 Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Stock

Steven A. Shallcross Purchases 25,000 Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Stock

Steven A. Shallcross 购买了 Theriva Biologics, Inc.（纽约证券交易所美国股票代码：TOVX）的25,000股股票
Financial News Live ·  2023/01/28 05:47

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Rating) CEO Steven A. Shallcross acquired 25,000 shares of the firm's stock in a transaction on Wednesday, January 25th. The stock was purchased at an average cost of $0.87 per share, with a total value of $21,750.00. Following the purchase, the chief executive officer now owns 160,000 shares of the company's stock, valued at $139,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Theriva Biologics, Inc.（纽约证券交易所代码：TOVX — 获取评级）首席执行官史蒂文·沙尔克罗斯在1月25日星期三的一笔交易中收购了该公司25,000股股票。该股票的平均购买成本为每股0.87美元，总价值为21,750.00美元。收购后，首席执行官现在拥有该公司16万股股票，价值139,200美元。该交易是在向美国证券交易委员会提交的文件中披露的，该文件可在 这个超链接。

Theriva Biologics Stock Performance

Theriva 生物制剂股票表现

Shares of NYSEAMERICAN TOVX opened at $0.90 on Friday. Theriva Biologics, Inc. has a 1 year low of $0.39 and a 1 year high of $4.39.

纽约证券交易所TOVX的股价周五开盘价为0.90美元。Theriva Biologics, Inc.创下1年低点0.39美元，创1年高点4.39美元。

Get
获取
Theriva Biologics
Theriva 生物制剂
alerts:
警报：

About Theriva Biologics

关于 Thriva Biologics

(Get Rating)

（获取评分）

Theriva Biologics, Inc is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C.
Theriva Biologics, Inc是一家处于临床阶段的公司，致力于开发保护微生物组以保护和恢复患者健康的疗法。其产品组合包括 SYN-020 和 SYN-004。SYN-020 旨在防止抗生素介导的微生物组损伤，C.

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Theriva Biologics (TOVX)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market
  • 免费获取 StockNews.com 关于 Theriva Biologics (TOVX) 的研究报告
  • MarketBeat Week 回顾 — 1/23-1/27
  • 为什么 Lucid 在一天之内飙升了近 100%
  • 利用这些铁路股票实现增长和收入
  • ASML 预计今年对芯片的需求将上涨，提振了销售前景
  • KLA 公司：在陷入困境的半市场中的实力

Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 Theriva Biologics 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Theriva Biologics及相关公司的最新新闻和分析师评级的简明每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发